Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study

INTRODUCTION: MVC-COV1901 is a protein subunit COVID-19 vaccine based on the stable prefusion spike protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide. Interim results of a phase 2 clinical trial demonstrated favorable safety profile and immunogenicity and the vaccine has been authorized f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Szu-Min, Chang, Shan-Chwen, Cheng, Hao-Yuan, Shih, Shin-Ru, Lien, Chia En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112257/
https://www.ncbi.nlm.nih.gov/pubmed/35579840
http://dx.doi.org/10.1007/s40121-022-00652-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112257/
https://www.ncbi.nlm.nih.gov/pubmed/35579840
http://dx.doi.org/10.1007/s40121-022-00652-6

Ejemplares similares